Transgene Stock

Transgene ROIC

The Return on Invested Capital (ROIC) of Transgene (TNG.PA) as of Aug 22, 2026 is -133.55 %. In the previous year, Return on Invested Capital (ROIC) was -68.04 % — a change of 96.29% (lower).

ROIC

-133.55 %

YoY

96.29%

Last updated:

Return on Invested Capital (ROIC) of Transgene is 2026 -133.55 % . Return on Invested Capital (ROIC) of Transgene was 2025 -68.04 % . It decreases by 96.29% lower compared to the previous year.

The Transgene ROIC history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROIC
Date
ROIC
Jan 1, 2017
-45.93 EUR
Jan 1, 2018
13.00 EUR
Jan 1, 2019
-23.04 EUR
Jan 1, 2020
-31.12 EUR
Jan 1, 2021
-27.49 EUR
Jan 1, 2022
-63.87 EUR
Jan 1, 2023
-68.04 EUR
Jan 1, 2024
-133.55 EUR
The Transgene ROIC history
YEARROICYoY
-133.55 %+96.29%
-68.04 %+6.52%
-63.87 %+132.31%
-27.49 %-11.64%
-31.12 %+35.07%
-23.04 %-277.26%
13.00 %-128.30%
-45.93 %+67.18%
-27.48 %-62.70%
-73.66 %+63.91%
-44.94 %
Access this data via the Eulerpool API

Transgene Stock analysis

What does Transgene do? Transgene SA is a French biotechnology company specializing in the development and production of therapeutics, with a focus on cancer medications. It has a strong patent portfolio in the field of viral vectors, which are used for targeted gene therapy. The company's main areas of operation are clinical trials, research, and production. Transgene has research and production facilities in Strasbourg and Lyon, with over 100 employees. It has established partnerships with pharmaceutical companies, including Takeda Pharmaceuticals, for the development and marketing of therapeutics. Its flagship product, OncoVir-1®, is an immunomodulator that stimulates the immune system to fight tumor cells. Another promising product is TG4010, a therapeutic vaccine for non-small cell lung carcinoma. Transgene is an emerging company with a promising portfolio of cancer therapeutics, leveraging its expertise in viral vectors and collaborating closely with industry partners to expedite the development of marketable products. Transgene is expected to play a significant role in the development of new and innovative cancer treatments. Transgene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Transgene stock

Return on Invested Capital (ROIC) of Transgene is -133.55 % in 2026.

Return on Invested Capital (ROIC) of Transgene changed from -68.04 % to -133.55 %, representing a 96.29% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Invested Capital (ROIC) Transgene since 2006 – with annual values, charts, and detailed analysis.

ROIC measures how effectively a company uses its invested capital to generate profits. A ROIC above the cost of capital creates shareholder value.

ROIC = NOPAT / Invested Capital

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Invested Capital (ROIC)'s Transgene with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Invested Capital (ROIC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Invested Capital (ROIC).

Access this data via the Eulerpool API

Profitability — Transgene

All Key Metrics — Transgene